News and Announcements
Cellmid Limited – Midkine Antibodies Effective in Cancer
- Published October 04, 2013 10:51AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Anti-midkine antibodies reduce tumour growth and spread
- Anti-angiogenic mechanism of action also evident
- Final studies in the programme to determine Cellmid’s clinical direction
SYDNEY, Thursday, 03 October 2013: Cellmid Limited (ASX: CDY) is pleased to advise that it has now completed its several cancer xenograft efficacy and mechanism of action studies using the company’s lead anti-midkine (MK) antibody with compelling results.
The MK antibody treatment slowed primary tumour growth, reduced cancer spread (metastasis) and slowed the formation of new blood vessels (angiogenesis) in different tumour types. These findings complete the Company’s extensive preclinical programme to determine clinical direction for its MK antibodies.
The findings of the current studies have been consistent with the results published recently by an independent research group (Hao, et al. Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer (2013) http://www.ncbi.nlm.nih.gov/pubmed/23976985)and add to the growing evidence of midkine’s importance in cancer.
To read the full ASX Release please click on the document below.
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
